Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NARecruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

September 27, 2028

Study Completion Date

September 27, 2029

Conditions
Barrett EsophagusGastroesophageal RefluxEsophageal Adenocarcinoma
Interventions
DEVICE

EsoCheck

FDA-approved, non-endoscopic, encapsulated swallowable balloon. EsoCheck will produce a sample which will subsequently be tested with EsoGuard assay. The EsoCheck is performed and completed in approximately 5 minutes.

DIAGNOSTIC_TEST

EsoGuard

Approved laboratory, methylated DNA panel that detects esophageal neoplasia. The EsoGuard assay tests the EsoCheck samples to detect BE in GERD participants.

Trial Locations (5)

21287

NOT_YET_RECRUITING

Johns Hopkins Hospital, Baltimore

44016

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

44195

NOT_YET_RECRUITING

Cleveland Clinic Taussig Cancer Center, Cleveland

80045

NOT_YET_RECRUITING

University of Colorado, Aurora

027599

NOT_YET_RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER